Calithera Biosciences, Inc. (NASDAQ:CALA – Get Free Report) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.00 and traded as high as $0.0002. Calithera Biosciences shares last traded at $0.0002, with a volume of 235 shares.
Calithera Biosciences Stock Performance
The firm has a market cap of $974.00, a PE ratio of 0.00 and a beta of -3.12.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is focused on the discovery and development of small molecule inhibitors that target metabolic pathways critical to the growth and survival of cancer cells. By disrupting tumor metabolism, Calithera aims to create novel therapeutic options for patients with solid tumors and hematologic malignancies.
The company’s pipeline includes lead candidates such as telaglenastat (CB-839), a glutaminase inhibitor being evaluated in multiple Phase 2 trials across various tumor types, and CB-1158, an arginase inhibitor designed to reprogram the tumor microenvironment and enhance anti-tumor immunity.
Further Reading
- Five stocks we like better than Calithera Biosciences
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
